Catalyst

Slingshot members are tracking this event:

Roche Plans to File for Marketing Authorization and Submit Data to Global Regulatory Authorities for Ocrelizumab

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
RHHBY Community voting in process

Additional Information

Additional Relevant Details "Roche plans to pursue marketing authorization for both PPMS and relapsing multiple sclerosis (RMS), a more common form of the disease, and will submit data from three pivotal Phase III studies to global regulatory authorities in the first half of 2016."  The drug, Ocrelizumab, is a breakthrough therapy drug designed to treat both PPMS and RMS.  
http://www.roche.com...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 28, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ocrelizumab, Marketing Authorization